Parkinson's disease (PD) is a neurodegenerative pathology on the rise worldwide. There is a demand for new therapeutic options that contribute to more quality of life and autonomy for people with PD. Recent studies suggest the therapeutic potential of medicinal cannabinoids for neurological pathologies. This manuscript aimed to review the use of medicinal cannabinoids in PD to provide an updated overview and verify new demands. A scoping review was conducted with the search of references in Databases, grey literature, and manual search. Articles in Portuguese, Spanish, or English with no date restriction were included. Ninety-five articles published between 1990 and 2022 were eligible for the final sample, originating mainly in the USA and Brazil. As for the administration, the oral route was the most common and several symptoms showed improvement after the use of cannabinoids, highlighting: rest tremor, muscle rigidity, bradykinesia, dyskinesia, pain, insomnia, and anxiety. The most common undesirable effects were: dizziness, drowsiness, hallucinations, and xerostomia. It was observed studies with sample bias, recall bias, information bias and non-response bias, and low quality of evidence. To produce the evidence desired by all actors interested in the use of medicinal cannabinoids and their products, double-blind, multicentre randomized clinical trials are necessary with experimental, control and placebo, and follow-up groups, to evaluate the neurological potential of the cannabinoids in PD and elaborate systematic review protocols without language restriction, with a larger number of Databases and grey literature.